4,901 trials
Fungal Infection
Primary: Single Dose Trough Concentration of IV Posaconazole (Cmin) — 318; 295; 467 ng/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 130.58; 124.53 ng/mL
Pharmacokinetics
Primary: Tear Fluid Levels — 113.633 μg/g
Prostate Cancer
Primary: Maximum Tolerated Dose of Samarium-153 — 2.0 mCi/kg
Postmenopausal Osteoporosis
Primary: Ratio of Pharmcokinetic (PK) Area Under the Concentration Time Curve (AUC) Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1…
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel Test and Reference Formulation — 28.6; 28.1 nanograms per milliliter (ng/mL)
Brain Metastases
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Vorinostat and Radiotherapy in Patients With Brain Metastases. — 300 mg
Chronic Obstructive Pulmonary Disease
Primary: Incidence of Adverse Events — 3; 3; 6; 7 Participants
Asthma
Primary: Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010 — 303.5; 106.2; 239.9; 434.5 pg/mL
Healthy
Primary: AUC(0-2hrs) of Pulmonary Arterial Systolic Pressure (PASP) Over Time Post 1st Dose — 2794.93; 2580.06; 2497.71 mmHg*min
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 177.69; 172.64 ng/ml
Healthy
Primary: Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 Minutes — 408.8; 409.6; -4.7; -4.6 milliseconds
Healthy
Primary: Cmax of Dihydroergotamine After MAP0004, MAP0004 Co-administered With Ketoconazole, and IV DHE Administration — 2582.507; 2495.100; 27771.234 pg/ml
Inflammation · Rheumatoid Arthritis
Primary: Frequency of Adverse Events — 5; 4; 3; 4 events
Calcium Deficiency · Vitamin D Deficiency
Primary: Amount of Calcium Excreted in Urine From 0 Hours up to 6 Hours Post Dose (Ca2+ Ae0-6h) — 1.07; 0.63 mmol